Hosted on MSN2mon
Applied Therapeutics' Govorestat Faces 'Significant' Uncertainty in Galactosemia Treatment After FDA Rejection, RBC Says
Late Wednesday, the clinical-stage company said the FDA is unable to approve govorestat's new drug application for the treatment of classic galactosemia in its current form amid "deficiencies" in ...
Hosted on MSN2mon
APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA
It also significantly reduced plasma galactitol levels in adults and children with galactosemia. Additional studies provided strong efficacy and safety data across 185 classic galactosemia ...
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against Applied Therapeutics (APLT)
If you are an investor in Applied Therapeutics and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) ...
TMCnet4d
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its ...
FDA 拒绝批准 Govorestat 治疗经典半乳糖血症
美国食品药品监督管理局（FDA）已向 Applied Therapeutics 公司发出了一份完整回复函（CRL），涉及 govorestat 用于治疗经典半乳糖血症的新药申请（NDA）。 该 NDA 包含 1/2 期 ...
INVESTOR DEADLINE TUESDAY: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - APLT
February 14, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and ...